glucose-dependent insulinotropic polypeptide receptor antagonists; insulin secretion; antihyperglycemic activity; dipeptidyl peptidase IV; fatty acid conjugation GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP), along with its counterpart glucagon-like peptide-1 (GLP-1), is one of the major mediators of postprandial glucose-induced insulin secretion (4) . As such, GIP is implicated as one of the factors responsible for hyperinsulinemia that occurs in obesity and type 2 diabetes, possibly as a result of an overactive enteroinsular axis (5) . Elevated plasma GIP concentrations are reported in both obese diabetic ob/ob mice (14) and in subjects with type 2 diabetes (5, 35) .
GIP is released postprandially following nutrient ingestion, especially fat, which makes it a potentially important anabolic agent in obesity etiology either directly by promoting hyperinsulinemia or indirectly through effects on lipoprotein lipase (LPL) activity. LPL plays a key role in the hydrolysis of circulating triacylglycerol, liberating nonesterified fatty acids for uptake and storage within the adipocyte (40) . GIP stimulates the synthesis and secretion of LPL in rat adipose tissue (10, 23) . Therefore, high circulating concentrations of GIP accompanied by high-fat energy feeding facilitate the uptake of triacylglycerol, all of which may contribute to increased adiposity (9, 10, 23) .
A likely link exists between GIP and obesity, which is further supported by studies that demonstrate that GIP enhanced insulin-stimulated glucose transport through increased adipocyte sensitivity (36) , increased fatty acid synthesis in adipose tissue explants (1, 30) , and reduced glucagon-stimulated lipolysis (8) .
Recent studies using GIP receptor (GIP-R) knockout mice demonstrated a phenotype associated with intolerance and diminished insulin secretion (29) . Furthermore, knockout of the GIP-R conferred resistance to diet-induced obesity and protection from insulin resistance (28) . Cross-breeding with obese diabetic ob/ob mice resulted in decreased body weight gain and significant amelioration of adiposity and insulin resistance despite hyperphagia comparable with control ob/ob mice (28) .
These studies suggest that disruption of the GIP signaling pathway by use of GIP-R antagonists could theoretically prevent obesity and insulin resistance, making it a target worth investigating for treatment of type 2 diabetes. NH 2 -terminally truncated GIP fragment peptides such as GIP-(3-42) have been shown to act as antagonists in vivo (17) , although this has not been found to be the case in vivo in a recent report (7) . However, of most utility thus far is (Pro 3 )GIP, which is a specific GIP-R antagonist capable of abolishing GIP's actions both in vitro and in vivo (18, 22) . Acute administration of (Pro 3 )GIP with an intraperitoneal injection of glucose exacerbates glycemic and insulinotropic excursions thought to be due to both inhibition of the insulinotropic actions of high levels of endogenous GIP (14, 15) and blocking of other extrapancreatic glucose-lowering actions (31) .
Long-term administration of (Pro 3 )GIP to ob/ob mice resulted in reductions of basal glucose and insulin concentrations and improvement of glucose and meal tolerance together with a change toward normalization of islet morphology and ␤-cell function (20) . These actions are underlined by significant improvement by (Pro 3 )GIP of insulin resistance that is otherwise particularly severe in this animal model of type 2 diabetes (2).
The present study has investigated the acute and long-term effects of another novel Glu 3 -substituted GIP-related peptide analog, (Hyp 3 )GIP. Furthermore, a daughter analog modified to contain a [C 16 ]palmitate fatty acid at the position Lys 16 residue was produced with the aim of providing a longer-acting molecule due to promotion of albumin binding in vivo. Evaluation of the in vitro properties of these novel GIP analogs was carried out alongside parallel studies using the established antagonist (Pro 3 )GIP (18) . Finally, the effects of 14 days of treatment with daily (Hyp 3 )GIP and (Hyp 3 )GIPLys 16 PAL were examined in obese diabetic ob/ob mice to establish their antidiabetic potential.
MATERIALS AND METHODS
Reagents. HPLC grade acetonitrile was obtained from Rathburn (Walkersburn, Scotland). Sequencing grade trifluoroacetic acid (TFA), dipeptidyl peptidase IV (DPP IV), 3-isobutyl-1-methylxanthine (IBMX), adenosine 3,5,-cyclic monophosphate (cAMP), adenosine 5Ј-triphosphate (ATP), and ␣-cyano-4-hydroxycinnamic acid were all purchased from Sigma (Poole, Dorset, UK). ␣-Fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids and peptide synthesis reagents were obtained from Calbiochem Novabiochem (Beeston, Nottingham, UK). RPMI 1640 and DMEM tissue culture medium, fetal bovine serum, penicillin, and streptomycin were all purchased from GIBCO (Paisley, Strathclyde, Scotland). The chromatography columns used for cAMP assay, Dowex AG 50WX and neutral alumina AG7, were obtained from Bio-Rad (Life Science Research, Alpha Analytical, Larne, Northern Ireland). Tritiated adenine (TRK311) was obtained from Amersham Pharmacia Biotech (Amersham, Bucks, UK). All water used in these experiments was purified using a Milli-Q water purification system (Millipore, Milford, MA). All other chemicals used were of the highest available purity.
Synthesis, purification, and characterization of GIP peptides. Native GIP was sequentially synthesized, as described previously (32) , on an Applied Biosystems automated peptide synthesizer (Model 432A; Synergy, Foster City, CA) with a preloaded Fmoc-Gln(Trt)-Wang resin using standard solid-phase Fmoc peptide chemistry (12 16 PAL incubations. The absorbance was monitored at 214 nm on a SpectraSystem UV2000 detector (Thermoquest Limited, Manchester, UK).
Cell culture. Chinese hamster lung fibroblasts (CHL cells, ATCC CCL39) stably transfected with the human GIP-R (25) were cultured in DMEM tissue culture medium containing, 10% (vol/vol) fetal bovine serum (FBS), 1% (vol/vol) antibiotic (100 U/ml penicillin, 0.1 mg/ml streptomycin), and 1.1 mM glucose. BRIN-BD11 cells were cultured in RPMI 1640 tissue culture medium containing 10% (vol/ vol) FBS, 1% (vol/vol) antibiotic (100 U/ml penicillin, 0.1 mg/ml streptomycin), and 11.1 mM glucose as described previously (27) . Cells were cultured in sterile vented tissue culture flasks (Corning Glass Works, Corning, NY) at 37°C in an atmosphere of 5% CO2 and 95% air using a LEEC incubator (Laboratory Technical Engineering, Nottingham, UK).
cAMP production. CHL cells were harvested and seeded into 24-well plates (Nunc, Roskilde, Denmark) at a density of 3.0 ϫ 10 5 cells per well loaded with TRK311 (2 Ci, TRK311; Amersham, Buckinghamshire, UK) and allowed to grow for 18 h. The culture medium was removed and cells subsequently washed twice with 2 ml of ice-cold Hanks' buffered saline (HBS) buffer (130 mM NaCl, 20 mM HEPES, 0.9 mM NaHPO4, 0.8 mM MgSO4, 5.4 mM KCl, 1.8 mM CaCl2, 5.6 mM glucose, and 25 mol/l phenol red, pH 7.4). The cells were then exposed to varying concentrations of GIP peptides(10 Ϫ13 to 10 Ϫ7 M) in HBS buffer supplemented with 1 mM IBMX for 20 min at 37°C. Similarly for the antagonist studies, varying concentrations (10 Ϫ13 to 10 Ϫ7 M) of GIP peptides were added in the presence of GIP (10 Ϫ7 M). The medium was subsequently removed and the cells lysed with 1 ml of lysing solution (5% TCA, 3% SDS, and 92% H2O, also containing 0.1 mM unlabeled cAMP and 0.1 mM unlabeled ATP). The intracellular tritiated cAMP was then separated on Dowex and alumina exchange resins, as described previously (39) .
Insulin secretion. BRIN-BD11 cells were harvested and seeded into 24-well plates (Nunc) at a density of 1.5 ϫ 10 5 cells/well and allowed to attach overnight in culture medium at 37°C. Culture medium was Data are means Ϯ SE and represent molecular masses or %intact peptide remaining (following HPLC separation) relative to the major degradation fragment glucose-dependent insulinotropic polypeptide (GIP)-(3-42) after incubation for 0 -8 h with dipeptidyl peptidase IV (DPP IV). The reactions were performed in triplicate. *P Ͻ 0.001 compared with native GIP. then removed, and 1.0 ml Krebs-Ringer bicarbonate buffer (KRB, 115 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl 2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM HEPES, and 10 mM NaHCO3, pH 7.4 with NaOH) supplemented with 0.1% (wt/vol) BSA and 1.1 mM glucose was added to each well. The cells were then incubated for 40 min at 37°C, after which the buffer was removed and replaced with fresh KRB (1.0 ml) supplemented with 5.6 mM glucose and a range of concentrations (10 Ϫ13 to 10 Ϫ7 M) of GIP or GIP analogs. Likewise, varying concentrations of GIP peptides (10 Ϫ13 to 10 Ϫ7 M) were added with GIP (10 Ϫ7 M) for the antagonist studies. After a 20-min incubation at 37°C, the buffer was removed from each well (900 l) and (200 l) aliquots used for measurement of insulin by RIA (13) .
Acute in vivo biological activity. Following an 18-h fast, plasma glucose and insulin responses were evaluated using 14-to 18-wk-old obese diabetic ob/ob mice (2). Responses were measured immediately prior to and following administration by intraperitoneal injection (n ϭ 8) of glucose alone (18 mmol/kg body wt) as control or glucose together with GIP or GIP peptides (25 nmol/kg body wt). These tests were performed to evaluate whether either of the two Hyp-substituted analogs had any GIP agonist activity. In addition, to assess the antagonistic properties of these peptides, a double dose of GIP (50 nmol/kg body wt) or GIP (25 nmol/kg body wt) in combination with each GIP analog peptide (25 nmol/kg body wt) was given by intraperitoneal injection. Fasted mice were used to maximize glycemic and insulin responses to enable evaluation of the effects of GIP peptides. All animal studies were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986. Protocol approval was granted under appropriate project licences by HPSS in Northern Ireland.
Longer-term in vivo studies. Obese diabetic ob/ob mice aged 14-to 18-wk (22) were randomly divided into groups that received once daily intraperitoneal injections (1700) of saline vehicle, (Hyp 3 )GIP, or (Hyp 3 )GIPLys 16 PAL (25 nmol/kg body wt) over 14 days. Food intake and body weights were recorded daily. Blood samples were taken at 0900 at 3-to 4-day intervals for plasma glucose and insulin analysis. A number of metabolic tests were carried out after 14 days treatment and again 14 days after cessation of treatment. These included evaluation of the effects in nonfasted mice of intraperitoneal glucose (18 mmol/kg body wt), glucose together with GIP (25 nmol/kg body wt), or insulin (50 U/kg body wt). Mice fasted for 18 h were used to evaluate responses to 15-min refeeding. In one experimental series, the pancreases of mice treated for 14 days were resected for determination of insulin content and islet morphometry, as described previously (20) .
In both acute and longer-term studies, test solutions were administered in a final volume of 5 ml/kg body wt. Blood samples were collected from the cut tip of the tail vein of conscious mice into chilled fluoride/heparin coated glucose microcentrifuge tubes (Sarstedt, Nüm-brecht, Germany) at the times indicated in the figures. Blood samples were immediately centrifuged using a Beckman microcentrifuge (Beckman Instruments, High Wycombe, Buckinghamshire, UK) for 30 s at 13,000 g. The resulting plasma was then aliquoted into fresh Eppendorf tubes and stored at Ϫ20°C prior to glucose determination using a Beckman Glucose Analyzer II (37) and insulin determination by RIA (13) .
Statistical analysis. Results are expressed as means Ϯ SE. Data were compared using Student's t-test or ANOVA, followed by the Student-Newman-Keuls post hoc test, as appropriate. Groups of data were considered to be significantly different if P Ͻ 0.05.
RESULTS
Degradation by DPP IV. As shown in Table 1 , native GIP was rapidly degraded by DPP IV to the truncated metabolite GIP-(3-42), with an estimated in vitro half-life of 1.3 h. In contrast, (Pro (Table 1) .
cAMP production in vitro. GIP analogs tested at 10 Ϫ7 M concentrations were considerably less potent than native GIP in stimulating cAMP production in GIP-R-transfected CHL fibroblasts ( 16 PAL significantly inhibited cAMP formation 34 -52% (P Ͻ 0.01 to P Ͻ 0.001).
Insulin secretion in vitro. 16 PAL inhibited maximal GIP-induced insulin secretion by 29 -38% (P Ͻ 0.05 to P Ͻ 0.001). There were no significant differences between any of the in vitro properties of the three GIP analogs ( Table 2 ). The basal insulin secretion as measured in an acute test was (means Ϯ SE, n ϭ 8) 1.82 Ϯ 0.14 ng⅐10 6 cell Ϫ1 ⅐20 min Ϫ1 at 5.6 mM glucose alone (control). This was 66 Ϯ 2% of the maximum insulin response observed with 10 Ϫ7 M native GIP.
Acute metabolic effects in ob/ob mice. Figure 1A shows the plasma glucose responses to intraperitoneal glucose alone or in combination with GIP or its analogs. Injection of GIP reduced the glycemic excursion at 30 and 60 min and significantly lowered (P Ͻ 0.001) area under the curve Results are presented as a %maximum GIP response at 10 Ϫ7 M (%means Ϯ SE and means Ϯ SE ng ⅐ 10 6 cells Ϫ1 ⅐ 20 min Ϫ1 for cAMP and insulin, respectively; n ϭ 4). cAMP production and insulin-releasing activity were measured in 2 separate cell lines, namely GIP receptor-transfected Chinese Hamster Lung fibroblast cells and glucose-responsive BRIN-BD11 pancreatic ␤-cells, respectively. *P Ͻ 0.01; †P Ͻ 0.001 compared with native GIP. Basal unstimulated levels were 5.05 Ϯ 0.55% and 1.82 Ϯ 0.14 ng ⅐ 10 6 cells Ϫ1 ⅐ 20 min Ϫ1 at 5.6 mM glucose control, respectively. Agonist effects were evaluated in the absence of added GIP, whereas possible antagonist actions were evaluated in the presence of 10 Ϫ7 M GIP.
(AUC) values (Fig. 1B) . In contrast, glucose concentrations and AUC measurements were significantly greater following (Pro GIPLys 16 PAL were significantly less (P Ͻ 0.05 to P Ͻ 0.01) than to GIP (Fig. 1D) . Native GIP caused significantly greater insulin release than glucose alone (P Ͻ 0.05). PAL on the glucose-lowering and insulinotropic actions of GIP administered together with glucose are shown in Fig. 2, A-D . Glucose levels were significantly higher (P Ͻ 0.05 to P Ͻ 0.001) at 15, 30, and 60 min after injection compared with native GIP alone. AUC values (Fig. 2B) showed that the overall glucose responses were 1.8-fold greater (P Ͻ 0.001) than for native GIP. Insulinotropic actions of GIP were diminished 1.2-to 1.8-fold (P Ͻ 0.05 to P Ͻ 0.001) by coadministration of each of the three GIP analogs over the 0-to 60-min study period (Fig. 2D) (Fig. 3, A and B) . Plasma glucose was significantly reduced (P Ͻ 0.05) following (Hyp 3 )GIP, but not (Hyp 3 )GIPLys 16 PAL, on day 12 (Fig. 4A ). As shown in Fig.   4B , insulin concentrations were unaffected by treatment with the GIP analogs. Figure 5 shows the effect of 14-day treatment with (Hyp 3 )GIP or (Hyp 3 )GIPLys 16 PAL on glucose tolerance and insulin responses. Glucose concentrations were significantly lower (P Ͻ 0.01) for both peptide-treated groups compared with salinetreated controls at both basal (t ϭ 0) as well as 15-min postinjection. The glucose concentration for the (Hyp 3 )GIPtreated group remained significantly reduced at 60-min postinjection (P Ͻ 0.05). Plasma insulin was significantly reduced (P Ͻ 0.01) at 15-min postinjection in the (Hyp 3 )GIP-treated group (Fig. 5B) (Fig. 6, A and B) . Longer-term effects on glucose and insulin responses to intraperitoneal injection of GIP in ob/ob mice. Glucose levels were significantly lower (P Ͻ 0.05 to P Ͻ 0.01) at basal and 15 min postinjection with GIP for both peptide-treated groups compared with saline controls (Fig. 8A) . However, at 60 min, glucose was significantly decreased (P Ͻ 0.01) in (Hyp   3   ) GIPtreated mice compared with the (Hyp 3 )GIPLys 16 PAL-treated group. There were no significant differences in the corresponding insulin responses following a GIP challenge, as shown in Fig. 8B . Thus this indicates that the action of the fatty acid-linked GIP-R antagonist (Hyp 3 )GIPLys 16 PAL may be acting through mechanisms other than blocking the direct insulinotropic actions to induce its potent hyperglycemic effects (Fig. 6B) .
Longer-term effects on glucose and insulin responses to intraperitoneal injection of glucose in ob/ob mice.

Effects of longer-term treatment with GIP analogs on pancreatic tissue. (Hyp
3
)GIP-and (Hyp 3 )GIPLys 16 PAL-treated groups exhibited significantly lower pancreatic insulin content (P Ͻ 0.05 to P Ͻ 0.01) compared with saline-treated control mice (Table 3 ). There was no significant difference in the average number of islets per section.
DISCUSSION
(Pro 3 )GIP has been developed as a powerful and effective specific GIP-R antagonist capable of completely abolishing the glucose-lowering and insulinotropic actions of GIP (18) . Daily administration of (Pro 3 )GIP for 11 days has been shown to ameliorate features of the ob/ob syndrome in mice, suggesting a therapeutic utility of GIP-R antagonists in obesity and/or diabetes (20) . This effect is pathology related, since chemical or molecular knockout of the GIP-R has little effect on glucose homeostasis in normal mice (22, 28) .
The present study has investigated the actions of another Glu 3 -substituted analog of GIP, (Hyp 3 )GIP, as a potentially new GIP-R antagonist. Hyp was selected because of its structural similarity to proline and the fact that it is unlikely to form a peptide bond that was susceptible to the action of DPP IV (33) . In addition to DPP IV-mediated degradation, recent reports (6) highlight the importance of renal filtration in elimination of GIP from the circulation. Structural modification of GIP to delay removal by the kidneys may therefore lead to a longer half-life. Thus we synthesized a daughter analog with palmitate conjugated to the ⑀-amino group of Lys 16 of (Hyp 3 )GIP. This was envisaged to facilitate binding to plasma proteins and thereby prevent clearance by the kidney. Already, such an approach has been used successfully with insulin (16, 25) and other peptide hormones, including GLP-1 (16, 24) .
As suspected, substitution of the third NH 2 -terminal amino acid of GIP with Hyp resulted in a stable enzyme-resistant analog that was unaffected by 8- (20, 22) . More importantly, (Hyp 3 )GIP but not the acylated analog induced a significant reduction in plasma glucose on days 12 and 14 of this study compared with saline-treated controls. Plasma insulin levels were not appreciably affected by either peptide, although there was a tendency toward lower levels. Such results indicate that peptide half-life was significantly enhanced or that the dose was high enough to overcome a short half-life. Presently available GIP antibodies react poorly with these analogs, and necessary pharmacokinetic studies to discriminate between these two possibilities await generation of new assay methods. These results also are reminiscent of the effects of (Pro 3 )GIP (20) and have parallel effects with Roux-en-Y gastric bypass in morbidly obese type 2 diabetic patients (34) . These individuals suffer loss of functional GIP secretory cells and demonstrate significantly decreased fasting plasma glucose within 2 wk. In contrast, insulin approached but never reached significantly reduced levels after 12 wk (3).
More convincing evidence for impact on blood glucose control comes from results of glucose tolerance tests conducted in ob/ob mice after 14 days treatment. This revealed significantly lower glucose concentrations in both (Hyp 3 )GIP and (Hyp 3 )GIPLys 16 PAL-treated groups. Plasma insulin levels in the (Hyp 3 )GIPLys 16 PAL group were significantly lower during the test, suggesting an increased effectiveness of insulin. This was indeed confirmed by increased hypoglycemic response to exogenous insulin in both of the groups treated with GIP analogs. These observations, together with previously published effects of (Pro 3 )GIP (20) , indicate that GIP-R antagonists alleviate obesity-related insulin resistance, which is a major driving force behind glucose intolerance, hyperglycemia, and ␤-cell dysfunction (19) .
Plasma glucose and plasma insulin responses to feeding following 14-day treatment with either (Hyp PAL, or saline gave similar plasma glucose concentrations. This was accompanied by unchanged insulin responses, arguing against an important inhibitory effect of GIP-R antagonism on intestinal glucose adsorption, as suggested by the results of some but not all relevant studies (11, 38) . This observation may also account for less pronounced lowering of nonfasting glucose than the glycemic responses to a large intraperitoneal glucose load. The possible involvement of changes in the expression of GIP-Rs on target cells in the beneficial effects of these analogs also merits further investigation, especially since downregulation has been reported in diabetic fatty Zucker rats (26) .
In conclusion, these studies indicate that (Hyp 3 )GIP and (Hyp 3 )GIPLys 16 PAL are effective GIP-R antagonists in vitro but are less effective than (Pro 3 )GIP in vivo. Nevertheless, the (Hyp 3 )-substituted analogs improved glucose tolerance of ob/ob mice after 14 days of treatment by enhanced insulin sensitivity and ␤-cell sparing. Acylation of (Hyp 3 )GIP appears to be of relatively little benefit and resulted in marginal impairment of in vivo activity compared with the parent molecule. Finally, since it might be speculated that GIP has an effect on leptin expression in the adipocyte, it is important to recognize that use of ob/ob mice has the limitation of representing a leptin-deficient model. Nevertheless, preliminary unpublished data indicate similar benefits of GIP-R antagonism in normal mice fed high-fat diets.
